Current Projects, Drug Therapy, Quality of Life Change
About This Project

Development of an oral formulation of the peptide angiotensin-(1-7) to reduce fibrosis

Investment summary

Constant Therapeutics (formerly Constant Pharmaceuticals) lead product, TXA127, is a pharmaceutical formulation of a naturally occurring peptide angiotensin-(1-7). It is currently delivered as a sub-cutaneous injection in many diseases, including COVID-19 and Duchenne Muscular Dystrophy, but this is not suitable for patients with EB.

TXA127 has demonstrated excellent results in a validated mouse model of Recessive Dystrophic Epidermolysis Bullosa (RDEB). In this model, TXA127, given as a daily subcutaneous injection, reduced fibrosis and significantly slowed the progression to pseudosyndactyly (mitten deformities, where repeated skin blistering followed by scarring causes a fusion of the fingers and toes).

The development for use in RDEB is in two parts. Part one is developing an oral formulation of TXA127 using a known delivery technology employing beta-cyclodextrins – the native peptide of TXA127 is not suitable for oral use, and sub-cutaneous delivery is not suitable for RDEB patients. Part two, involves a proof of concept Phase 2 clinical trial using oral TXA127 in patients with EB.

This programme of work is a collaborative effort with DEBRA Austria. For more details, read the Constant Therapeutics press release.